Advantage Investment Management’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Advantage Investment Management’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-755	Closed	-$32K	–	970
2016 Q2	$32K	Buy	755 +42	+6%	+$1.78K	0.02%	409
2016 Q1	$29K	Hold	713	–	–	0.01%	406
2015 Q4	$37K	Buy	713 +71	+11%	+$3.62K	0.02%	377
2015 Q3	$30K	Hold	642	–	–	0.02%	383
2015 Q2	$40K	Hold	642	–	–	0.02%	375
2015 Q1	$40K	Buy	+642	New	+$38.1K	0.02%	355

Other funds holding XPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

PVH

Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

KHLMVGHM

Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet Tel Aviv, Israel $2.44B AUM 24.95% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return

HCIA

Hochman Cole Investment Advisors Deerfield, Illinois $255M AUM 23.27% 1-Year Est. Return

Advantage Investment Management's XPH Position: Q3 2016 in Review

Advantage Investment Management sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q3 2016, closing a stake of 755 shares — an estimated $32K sold.

Advantage Investment Management first reported a position in XPH in Q1 2015 and held it in 6 quarters. The position peaked at $40K in Q2 2015. 69 funds tracked by Wall St. Rank hold XPH as of Q3 2016.

Advantage Investment Management reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q3 2016 after selling out during the quarter.
Advantage Investment Management sold 755 State Street SPDR S&P Pharmaceuticals ETF shares in Q3 2016, an estimated $32K.
Advantage Investment Management first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q1 2015 and held it in 6 quarters.
Advantage Investment Management's State Street SPDR S&P Pharmaceuticals ETF position peaked at $40K in Q2 2015.
69 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q3 2016.

Based on Advantage Investment Management's 13F filing for Q3 2016, filed 27 Mar 2017.